Microparticles and multi-unit systems for advanced drug delivery

被引:13
作者
Kallai-Szabo, Nikolett [1 ]
Farkas, Dora [1 ]
Lengyel, Milena [1 ]
Basa, Balint [1 ]
Fleck, Christian [1 ]
Antal, Istvan [1 ]
机构
[1] Semmelweis Univ, Dept Pharmaceut, Hogyes Str 7, H-1092 Budapest, Hungary
关键词
Pellets; Microspheres; Microparticulate; Microcapsules; Minitablets; Multiparticulate systems; Drug release; SOLID LIPID MICROPARTICLES; FAST-DISINTEGRATING TABLET; TASTE-MASKING; IN-VITRO; BIODEGRADABLE MICROSPHERES; EXTRUSION-SPHERONISATION; OCULAR DELIVERY; CYCLOSPORINE-A; RELEASE; FORMULATION;
D O I
10.1016/j.ejps.2024.106704
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Microparticles have unique benefits in the formulation of multiparticulate and multi-unit type pharmaceutical dosage forms allowing improved drug safety and efficacy with favorable pharmacokinetics and patient centricity. On the other hand, the above advantages are served by high and well reproducible quality attributes of the medicinal product where even flexible design and controlled processability offer success as well as possible longer product life-cycle for the manufacturers. Moreover, the specific demands of patients can be taken into account, including simplified dosing regimens, flexible dosage, drug combinations, palatability, and ease of swallowing. In the more than 70 years since the first modified-release formulation appeared on the market, many new formulations have been marketed and many publications have appeared in the literature. More unique and newer pharmaceutical technologies and excipients have become available for producing tailor-made particles with micrometer dimensions and beyond. All these have contributed to the fact that the sub-units (e.g. minitablets, pellets, microspheres) that make up a multiparticulate system can vary widely in composition and properties. Some units have mucoadhesive properties and others can float to contribute to a suitable release profile that can be designed for the multiparticulate formula as a whole. Nowadays, there are some available formulations on the market, which are able to release the active substance even for several months (3 or 6 months depending on the type of treatment). In this review, the latest developments in technologies that have been used for a long time are presented, as well as innovative solutions such as the applicability of 3D printing to produce subunits of multiparticulate systems. Furthermore, the diversity of multiparticulate systems, different routes of administration are also presented, touching the ones which are capable of carrying the active substance as well as the relevant, commercially available multiparticle-based medical devices. The versatility in size from 1 mu m and multiplicity of formulation technologies promise a solid foundation for the future applications of dosage form design and development.
引用
收藏
页数:25
相关论文
共 217 条
[51]   Development and evaluation of sustained release mini-matrices prepared via hot melt extrusion [J].
De Brabander, C ;
Vervaet, C ;
Remon, JP .
JOURNAL OF CONTROLLED RELEASE, 2003, 89 (02) :235-247
[52]  
Digenis G., 1994, MULTIPARTICULATE ORA, P333
[53]   Once versus three times daily dosing of oral budesonide for active Crohn's disease: A double-blind, double-dummy, randomised trial [J].
Dignass, Axel ;
Stoynov, Simeon ;
Dorofeyev, Andrey E. ;
Grigorieva, Galina A. ;
Tormova, Eva ;
Altorjay, Istvan ;
Tuculanu, Daniel ;
Bunganic, Ivan ;
Pokrotnieks, Juris ;
Kupcinskas, Limas ;
Dilger, Karin ;
Greinwald, Roland ;
Mueller, Ralph .
JOURNAL OF CROHNS & COLITIS, 2014, 8 (09) :970-980
[54]  
Diurnal Europe B.V, SUMMARY PRODUCT CHAR
[55]   A micro-XRT image analysis and machine learning methodology for the characterisation of multi-particulate capsule formulations [J].
Doerr, Frederik J. S. ;
Florence, Alastair J. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS-X, 2020, 2
[56]   Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability [J].
Doty, Amber ;
Schroeder, Jon ;
Kou Vang ;
Sommerville, Mark ;
Taylor, Mervin ;
Flynn, Brad ;
Lechuga-Ballesteros, David ;
Mack, Peter .
AAPS PHARMSCITECH, 2018, 19 (02) :837-844
[57]   Practical approaches of taste masking technologies in oral solid forms [J].
Douroumis, Dionysios .
EXPERT OPINION ON DRUG DELIVERY, 2007, 4 (04) :417-426
[58]   Production of pellets via extrusion-spheronisation without the incorporation of microcrystalline cellulose: A critical review [J].
Dukic-Ott, A. ;
Thommes, M. ;
Remon, J. P. ;
Kleinebudde, P. ;
Vervaet, C. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2009, 71 (01) :38-46
[59]   Enzyme Responsive Vaginal Microbicide Gels Containing Maraviroc and Tenofovir Microspheres Designed for Acid Phosphatase-Triggered Release for Pre-Exposure Prophylaxis of HIV-1: A Comparative Analysis of a Bigel and Thermosensitive Gel [J].
Ekama, Sabdat Ozichu ;
Ilomuanya, Margaret O. ;
Azubuike, Chukwuemeka Paul ;
Ayorinde, James Babatunde ;
Ezechi, Oliver Chukwujekwu ;
Igwilo, Cecilia Ihuoma ;
Salako, Babatunde Lawal .
GELS, 2022, 8 (01)
[60]   OPTIMIZATION OF SPRAY-DRIED AND SPRAY-CONGEALED LIPID MICROPELLETS AND CHARACTERIZATION OF THEIR SURFACE-MORPHOLOGY BY SCANNING ELECTRON-MICROSCOPY [J].
ELDEM, T ;
SPEISER, P ;
HINCAL, A .
PHARMACEUTICAL RESEARCH, 1991, 8 (01) :47-54